GLP-1 Evidence

Inmharthanacht

Cad a tharlaíonn nuair a stopann tú leighis GLP-1

Tagann an chuid is mó den mheáchan ar ais. Is é seo an toradh is tábhachtaí agus is lú a fhógraítear sa réimse, agus athraíonn sé an tuiscint ar cad atá na drugaí seo ann.

Updated 4 min read 21 citations Evidence strength 5/5

Táblaí cruinne scaoilte le cód aitheantais, feicthe ó thuas
Larry D. Moore · CC BY 4.0 · Wikimedia Commons

An t-experiment aistarraingthe

Rith STEP 1 ar feadh 68 seachtaine agus ansin stopadh an druga i ngach duine. Lean an leathnú ar rannpháirtithe ar feadh bliain eile as cóireáil [5]. Tar éis meáchan a chailliúint thart ar 17% ar an meán, d'athbhuaigh rannpháirtithe thart ar trí cheathrú de. D'athraigh na feabhsuithe i mbrú fola, lipidí agus marcóirí gliceamacha ar ais chuig an mbunlíne ar an am céanna.

Ní raibh sé seo mín, agus ní raibh sé ina subgroup. Is é an toradh lárnach a bhí ann sa leathnú.

Athbhuaigh meáchan tar éis stopadh

An t-experiment leanúnach

Chuaigh STEP 4 i dtreo eile. Rith gach duine ar semaglutide ar feadh 20 seachtaine; ansin cuireadh rannpháirtithe ar a gcéanna chun leanúint ar aghaidh nó chun dul ar placebo [6]. Lean na daoine a choinnigh ar aghaidh ag cailliúint meáchan ar feadh 48 seachtaine eile. D'athbhuaigh na daoine a cuireadh ar placebo. Céanna daonra, céanna pointe tosaigh, treochtaí in aghaidh, le difríocht amháin a bhí ann an raibh an druga ag leanúint.

Leanúnachas i gcomparáid le h-aistarraingt
TrialDearadhCóireáil leanúnachCóireáil stoptha
Leathnú STEP 1 [5]68 seachtaine ar, 52 seachtaine as—Athbhuaigh ≈ trí cheathrú de chailliúint
STEP 4 [6]20-seachtain rith isteach, ansin randomaitheCailliúint meáchain bhreiseAthbhuaigh gníomhach
STEP 5 [4]104 seachtaine leanúnachCailliúint coinnithe go 2 bhliain—
SELECT [3]~4 bliana leanúnachCailliúint coinnithe, imeachtaí laghdaithe—

Cén fáth nach bhfuil sé seo an scannal a léirítear uaireanta

Ní bhfaigheann aon duine go bhfuil sé damanta go n-ardóidh brú fola nuair a stopann tú le antihypertensive, nó go n-ardóidh cholesterol nuair a stopann tú le statin. Iompraíonn obair mar na coinníollacha chróineacha a bhfuil sé in aice: cóireáil é, feabhsaíonn na huimhreacha; tarraingíonn cóireáil siar, téann siad ar ais. Is é an fáth go dtéann sé seo i bhfeidhm go difriúil ná go bhfuil meáchan fós tuairimithe go forleathan mar cheist charachtair seachas mar cheist fhisiolaíoch, mar sin is cosúil go bhfuil cóireáil a chaithfidh leanúint mar theip seachas mar bhainistíocht galar chróineach gnáth [9].

Aontaíonn an léamh meicniúil. Má athraíonn na drugaí seo pointe socraithe, ní bheadh an meáchan ag teacht ar ais chomh hiontaofa sin. Cuireann siad isteach ar an ocras chomh fada agus atá siad i láthair, agus tagann an t-ocras ar ais nuair nach bhfuil siad ann.

Cad a athraíonn sé seo i gcleachtas

  • Is é an costas leanúnach, ní aon uair amháin. Déan measúnú ar inrochtanaíocht thar na blianta, ní thar chúrsa. Is é seo an chúis is coitianta a stopann daoine, agus tagann stopadh le tuairisc ar athbhuaigh.
  • Téann laige soláthair i bhfeidhm. Níl bearnaí neamhneodrach; is laige páirteach iad.
  • Tóg na nósanna le linn cóireála, ní tar éis. Tá sé i bhfad níos éasca na hoiliúnachtaí frithsheasmhachta agus an t-íoc próitéine a bhunú agus tú ag cur isteach ar an ocras. Cé nach bhfuil sé tástáilte go hiomlán, is iad na haicme levers amháin atá ar fáil. Féach cailliúint muscle.
  • Níl aon fianaise taobh thiar de tapering. Moltar go forleathan é agus tá sé go hiomlán tástáilte. D'fhéadfadh sé cabhrú; níor léirigh aon duine é.
  • Rinne na drugaí fós rud éigin inmharthana. Ní dhéanann athbhuaigh meáchain ceathair bliana de laghdú ar imeachtaí cardiovascular i duine a d'fhan ar chóireáil [3].
Táibléid bheaga bhána clúdaithe ag luí in aice lena stríoc foil
Rünno · Public domain · Wikimedia Commons

Ceisteanna coitianta

An athbhuaigh mé níos mó ná a chaill mé?
Taispeánann na sonraí trial athbhuaigh i dtreo an bhunlíne, ní thar a. Ní haon toradh é an overshoot sa staidéar aistarraingthe [5].
An gcabhraíonn tapering an dáta?
Is é an rud atá plauisble agus go hiomlán tástáilte. Níor thástáil aon trial a chuir deireadh le go tobann le taper.
An féidir liom é a thógáil go hidirnáisiúnta?
Níor thástáil aon trial a rinne regimens eatramhach. Ag breith ar an gcaoi a thosaíonn athbhuaigh go tapa tar éis aistarraingt, níl bunús fianaise ann chun súil a choinneáil air.
Cad faoi an dáta cothabhála íseal?
Fós neamhthástáilte mar straitéis shonrach. Tástáil STEP 4 leanúnachas ag an dáta iomlán i gcomparáid le placebo [6], ní i gcomparáid le dáta laghdaithe.
An raibh sé fiú é má thagann an meáchan ar ais?
Braitheann sé ar cad a bhí tú ag cóireáil. Má bhí an sprioc mar phictiúr bainise, d'fhéadfadh an freagra a bheith ní. Má bhí sé mar riosca cardiovascular, tharla na himeachtaí a cuireadh in iúl agus fanann siad cosanta [3].
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 12 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 1911meta-analysis (1)randomised trial (9)review (1)other (1)
9 foilsithe, 2016–2025. Tá trialacha anseo ach beagán sintéise, mar sin tá torthaí aonair fós an-tábhachtach agus d'fhéadfadh siad a bheith ag athrú. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  2. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  4. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  5. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  6. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  7. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial Rubino DM, Greenway FL, Khalid U, et al. · JAMA · 2022 · Randomised controlled trial DOIPubMed 35015037Full text
  8. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  9. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  10. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  11. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Wharton S, Calanna S, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 34514682Full text
  12. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  13. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33625476Full text
  14. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  15. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  16. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Frías JP, Auerbach P, Bajaj HS, et al. · The lancet. Diabetes & endocrinology · 2021 · Randomised controlled trial DOIPubMed 34293304
  17. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  18. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial Sorli C, Harashima SI, Tsoukas GM, et al. · The lancet. Diabetes & endocrinology · 2017 · Randomised controlled trial DOIPubMed 28110911
  19. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Marso SP, Bain SC, Consoli A, et al. · The New England journal of medicine · 2016 · Randomised controlled trial DOIPubMed 27633186
  20. Obesity Management in Adults: A Review Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. · JAMA · 2023 · Review DOIPubMed 38015216Full text
  21. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 · Journal article DOIPubMed 38976257Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original